Pan Cancer T

Name

Pan Cancer T

Legal name

Pan Cancer T B.V.

Website

https://pancancer-t.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

TCR-T Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• TCR-T cell therapy
• Solid tumor immunotherapy
• Adoptive cell therapy
• Oncology drug development
• Cancer cell therapy

Headquarters

HQ city

Rotterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. TCR-T Cell Therapy Development: Pan Cancer T is a preclinical/clinical-stage biotech company developing TCR-T cell therapies for solid tumors. The company is pre-revenue, having raised approximately €21 million in funding to advance its lead candidate PCT1:CO-STIM into first-in-human clinical trials. Revenue will be generated through clinical development and potential licensing/partnership deals with pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Pan Cancer T develops next-generation T cell receptor engineered T cell (TCR-T) therapies for solid tumors. Its lead clinical candidate, PCT1:CO-STIM, is an autologous cell therapy that reprograms patient T cells with a TCR specific for the ROPN1 cancer-restricted antigen, combined with the company's proprietary TCR:CO-STIM co-stimulatory technology to enhance T cell persistence within immunosuppressive solid tumor microenvironments. The therapy is being advanced toward first-in-human clinical trials in triple-negative breast cancer and melanoma, with an EMA regulatory filing planned for 2026.

Product overview

Pan Cancer T is developing next-generation TCR-T (T cell receptor engineered T cell) therapies for solid tumours. The company's core offering consists of PCT1:CO-STIM as its lead clinical program, a proprietary TCR discovery platform, and TCR:CO-STIM technology for enhancing T cell durability. The pipeline targets multiple solid cancers including triple-negative breast cancer, melanoma, colorectal, ovarian, bladder, prostate, skin, esophagus, lung, and brain cancers. PCT1:CO-STIM is an autologous T cell therapy that reprograms patient T cells to recognize and attack tumour cells expressing the ROPN1 antigen.

Differentiator

Problem solved

Functional benefit

Products and services

• PCT1:CO-STIM Pan Cancer T's lead clinical candidate: an autologous TCR-T cell therapy featuring an IP-protected T cell receptor highly specific for the ROPN1 tumor-restricted antigen (expressed in over 90% of triple-negative breast cancer and melanoma patients), incorporating the company's proprietary TCR:CO-STIM technology to enhance T cell fitness and persistence in solid tumors. Indicated initially for triple-negative breast cancer and melanoma.

Quantifiable outcome

• ROPN1 target expressed in over 90% of triple-negative breast cancer and melanoma patients
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• NecstGencoreStrategic or Co-development Partner · 16 January 2025Extended collaboration with Leiden-based NecstGen to include development and clinical manufacturing of retroviral vectors for PCT1:CO-STIM TCR-T cell production. NecstGen will develop scalable manufacturing process, establish Master Cell Bank, and be responsible for clinical supply of viral vectors. Both companies expect improved efficiency beyond current market standards and reduced time/costs for cell-based therapies.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Adaptimmune plc: Adaptimmune is the most established TCR-T company targeting solid tumors with its SPEAR-TCR platform (Tecelra approved for synovial sarcoma; MAGE-A4, MAGE-A10 programs). Multiple Pan Cancer T leaders came directly from Adaptimmune, and the two compete head-to-head in TCR-T for solid tumors with comparable target-discovery and engineering approaches.
• Immatics N.V. Immatics develops TCR-T cell therapies (ACTengine platform) targeting solid tumors with multiple clinical-stage assets and a complementary TCR Bispecifics program. It directly competes in TCR discovery, solid tumor targeting, and pharma partnership economics with Pan Cancer T.
• Iovance Biotherapeutics: Iovance is the leading commercial TIL (tumor-infiltrating lymphocyte) cell therapy company (Amtagvi approved for melanoma). It represents the most credible proof point for cell therapy in solid tumors and competes for the same patient populations and pharma partnership attention as Pan Cancer T.
• Lyell Immunopharma: Lyell is developing next-generation TIL and TCR-T cell therapies for solid tumors, focused on overcoming T cell exhaustion and improving persistence in the tumor microenvironment — directly parallel to Pan Cancer T's TCR:CO-STIM co-stimulation thesis.
• Neogene Therapeutics: Neogene Therapeutics was a TCR-T company developing personalized neoantigen-targeting T cell therapies for solid tumors, acquired by AstraZeneca in 2023 for up to $320M. It represents the closest comparable exit precedent for a TCR-T solid tumor company with a novel target-discovery approach similar to Pan Cancer T's.

Broad incumbents

• Allogene Therapeutics: Allogene is a leading allogeneic CAR-T cell therapy company with a broader portfolio across hematologic and solid tumor indications. While it focuses on allogeneic (off-the-shelf) rather than autologous TCR-T, it competes for the same pharma partnership and investor mindshare in cell therapy for cancer.

Emerging players

• Cellectis S.A. Cellectis is a gene-editing cell therapy company developing allogeneic CAR-T and TCR-T candidates (including TALEN-edited platforms). It competes in the broader engineered T cell therapy space and offers a comparison point for novel gene engineering approaches similar to Pan Cancer T's TCR:CO-STIM.
• Celyad Oncology: Celyad is a Belgian clinical-stage cell therapy company developing NKG2D-based CAR-T candidates for solid and hematologic cancers. Its TCR-NK-like receptor approach and clinical-stage status make it a relevant smaller-cap peer for Pan Cancer T.
• TILT Biotherapeutics: TILT Biotherapeutics develops oncolytic adenoviruses combined with immune checkpoint inhibitors and cell therapies for solid tumors. It is a Finnish/European clinical-stage peer addressing the same solid tumor challenge as Pan Cancer T through a complementary modality.
• Marker Therapeutics: Marker Therapeutics is a clinical-stage cell therapy company developing Multi-Antigen Targeted T cell therapies for solid tumors and lymphoma. It is a comparable early-stage US peer in the multi-tumor T cell therapy space where Pan Cancer T also operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pancancer-t

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pan Cancer T